1. Home
  2. CERO vs SPRC Comparison

CERO vs SPRC Comparison

Compare CERO & SPRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CERO
  • SPRC
  • Stock Information
  • Founded
  • CERO 2017
  • SPRC 2004
  • Country
  • CERO United States
  • SPRC Israel
  • Employees
  • CERO N/A
  • SPRC N/A
  • Industry
  • CERO
  • SPRC Biotechnology: Pharmaceutical Preparations
  • Sector
  • CERO
  • SPRC Health Care
  • Exchange
  • CERO Nasdaq
  • SPRC Nasdaq
  • Market Cap
  • CERO 3.5M
  • SPRC 3.4M
  • IPO Year
  • CERO N/A
  • SPRC N/A
  • Fundamental
  • Price
  • CERO $9.93
  • SPRC $0.30
  • Analyst Decision
  • CERO Strong Buy
  • SPRC
  • Analyst Count
  • CERO 2
  • SPRC 0
  • Target Price
  • CERO $45.00
  • SPRC N/A
  • AVG Volume (30 Days)
  • CERO 3.3M
  • SPRC 196.1K
  • Earning Date
  • CERO 08-13-2025
  • SPRC 02-15-2025
  • Dividend Yield
  • CERO N/A
  • SPRC N/A
  • EPS Growth
  • CERO N/A
  • SPRC N/A
  • EPS
  • CERO N/A
  • SPRC N/A
  • Revenue
  • CERO N/A
  • SPRC $1,306,000.00
  • Revenue This Year
  • CERO N/A
  • SPRC N/A
  • Revenue Next Year
  • CERO N/A
  • SPRC N/A
  • P/E Ratio
  • CERO N/A
  • SPRC N/A
  • Revenue Growth
  • CERO N/A
  • SPRC N/A
  • 52 Week Low
  • CERO $6.71
  • SPRC $0.20
  • 52 Week High
  • CERO $895.40
  • SPRC $1.79
  • Technical
  • Relative Strength Index (RSI)
  • CERO 50.09
  • SPRC 49.11
  • Support Level
  • CERO $8.12
  • SPRC $0.29
  • Resistance Level
  • CERO $13.14
  • SPRC $0.34
  • Average True Range (ATR)
  • CERO 2.83
  • SPRC 0.02
  • MACD
  • CERO 0.39
  • SPRC -0.00
  • Stochastic Oscillator
  • CERO 19.58
  • SPRC 33.33

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

About SPRC SciSparc Ltd.

SciSparc Ltd is a specialty clinical stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.

Share on Social Networks: